Abstract: Nagashima-Type palmoplantar keratosis (NPPK) is the most common palmoplantar keratosis in Asian population. In 2013, Kubo found that it was caused by homozygous or complex heterozygous mutations in serine protease inhibitor B7 (SERPINB7) by whole exome sequencing, and 15 different pathogenic mutations have been found at present. The typical clinical feature of NPPK is hyperkeratosis. NPPK has a good long-term prognosis, but there is still no standardized treatment. Current studies have found that gentamicin can effectively relieve skin hyperkeratosis and smell in patients with NPPK, but more clinical studies are needed to verify.

Key words: Nagashima-type palmoplantar keratosis, serine protease inhibitor, nonsense mutation, gentamicin